Management of Psoriasis Flare-Up

Introduction to Psoriasis Management

The American Academy of Dermatology recommends that systemic corticosteroids should be immediately tapered and discontinued, as they can precipitate or worsen psoriasis flares, especially upon withdrawal, and the patient should be transitioned to appropriate psoriasis-specific therapies 1, 2
Systemic corticosteroids like prednisone at high doses are contraindicated in psoriasis as they can precipitate erythrodermic psoriasis, generalized pustular psoriasis, or very unstable psoriasis, particularly when discontinued 1, 2

The British Medical Journal suggests initiating controlled tapering of prednisone, implementing a gradual taper schedule over several weeks to minimize withdrawal effects, and monitoring closely during the tapering period for signs of worsening disease 1, 3
The Journal of Clinical Oncology recommends consulting with dermatology for evaluation and management planning, considering skin biopsy if diagnosis is uncertain or to rule out other conditions, and using clinical photography to document progression 4
For mild-moderate disease, the Journal of Clinical Oncology suggests topical therapy with medium-to-high potency topical corticosteroids, and considering adding topical vitamin D analogs for synergistic effect, as well as topical emollients and antihistamines for symptomatic relief 4
For moderate-severe disease, Praxis Medical Insights recommends considering acitretin, phototherapy, or methotrexate, and for severe disease, immediate dermatology consultation, hospitalization if metabolically unstable, and initiating systemic therapy with acitretin, methotrexate, or cyclosporine 2, 5

The Journal of Clinical Oncology recommends weekly monitoring during the prednisone taper and transition to psoriasis-specific therapy, and regular assessment of disease activity using body surface area or PASI scoring 4, 6
The British Medical Journal suggests laboratory monitoring based on chosen therapy, such as liver function tests for methotrexate 1

The British Medical Journal states that systemic corticosteroids should only be used in psoriasis for specific conditions, such as persistent uncontrollable erythroderma, generalized pustular psoriasis, or hyperacute psoriatic polyarthritis, and avoiding drug interactions that may worsen the condition or interfere with new treatments 1, 2
The Journal of the American Academy of Dermatology recommends considering TNF-α inhibitors for patients who require immunosuppression for another condition, and adjusting dosing of certain medications for patients with higher body weight 7, 8

Praxis Medical Insights suggests explaining the risks of systemic corticosteroids in psoriasis and the need for appropriate therapy, discussing the chronic nature of psoriasis and the importance of long-term management, and emphasizing the importance of adherence to the tapering schedule and new treatment regimen 1, 2, 6

The British Medical Journal (BMJ) guidelines state that oral corticosteroids are contraindicated in psoriasis because dose reduction or abrupt cessation can precipitate life‑threatening complications such as erythrodermic psoriasis, generalized pustular psoriasis (von Zumbusch type), or severe unstable psoriasis with widespread skin involvement【9】.
According to the BMJ, the rebound phenomenon during tapering or withdrawal leads to a qualitative worsening of disease, not merely a return to baseline severity【9】.

The BMJ specifies three narrow indications where systemic corticosteroids may be considered: (1) persistent uncontrollable erythroderma with metabolic complications, (2) generalized pustular psoriasis of von Zumbusch type when alternative drugs are contraindicated, and (3) hyper‑acute psoriatic polyarthritis threatening irreversible joint damage【9】.

Registry data reported in the Annals of the Rheumatic Diseases show that systemic steroids are prescribed to up to 30 % of patients with psoriasis in some real‑world cohorts【10】.
The same source notes a lack of randomized clinical trial evidence supporting the efficacy of oral corticosteroids for psoriasis, while numerous case reports document severe adverse outcomes, justifying the strong contraindication【10】.

In psoriatic arthritis, low‑dose oral corticosteroids (≤7.5 mg/day) are used in approximately 30 % of patients, despite the absence of clinical trial data, as reported in the Annals of the Rheumatic Diseases【10】.
The American College of Rheumatology (ACR) recommends avoiding oral corticosteroids as monotherapy for psoriatic arthritis because of insufficient efficacy data and the risk of psoriasis flare【10】.
Intra‑articular corticosteroid injections are acceptable for persistently inflamed joints provided the injection site avoids psoriatic plaques, per the Annals of the Rheumatic Diseases【10】.

Patients with extensive baseline skin involvement have the highest risk of severe rebound when oral corticosteroids are withdrawn, as identified in the Annals of the Rheumatic Diseases【10】.
Rapid tapering (rather than a controlled, gradual reduction) markedly increases the likelihood of rebound flares【10】.
Absence of concomitant disease‑modifying antirheumatic drugs (DMARDs) or psoriasis‑specific therapy during tapering is a major predictor of severe rebound, according to the same source【10】.